TipRanks
Abbott Laboratories (DE:ABL)
NYSE:ABL
Germany Market
ABL
Abbott Laboratories
RESEARCH TOOLSreports

Abbott Laboratories (ABL) Stock Forecast & Price Target

25 Followers
See the Price Targets and Ratings of:

ABL Analyst Ratings

Strong Buy
19Ratings
Strong Buy
17 Buy
2 Hold
0 Sell
Based on 19 analysts giving stock ratings to
Abbott
Laboratories
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ABL Stock 12 Month Forecast

Average Price Target

€108.82
▲(19.47% Upside)
Based on 19 Wall Street analysts offering 12 month price targets for Abbott Laboratories in the last 3 months. The average price target is €108.82 with a high forecast of €120.47 and a low forecast of €102.63. The average price target represents a 19.47% change from the last price of €91.08.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"72":"€72","121":"€121","84.25":"€84.3","96.5":"€96.5","108.75":"€108.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":120.47450895,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€120.47</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":108.81748470437502,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€108.82</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":102.62643355,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€102.63</span>\n  </div></div>","useHTML":true}}],"tickPositions":[72,84.25,96.5,108.75,121],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,86.271,88.90203915000001,91.5330783,94.16411745,96.7951566,99.42619575,102.0572349,104.68827405,107.3193132,109.95035235,112.5813915,115.21243065,117.84346980000001,{"y":120.47450895,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,86.271,88.00534497725961,89.73968995451924,91.47403493177885,93.20837990903847,94.94272488629808,96.6770698635577,98.41141484081732,100.14575981807694,101.88010479533655,103.61444977259617,105.34879474985578,107.0831397271154,{"y":108.81748470437502,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,86.271,87.52911027307692,88.78722054615385,90.04533081923077,91.3034410923077,92.56155136538462,93.81966163846154,95.07777191153846,96.33588218461539,97.59399245769231,98.85210273076923,100.11021300384616,101.36832327692308,{"y":102.62643355,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":107.562,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":104.765,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":108.142,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":103.36,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":91.464,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":95.574,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":87.325,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":76.408,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":73.704,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":80.04,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":90.724,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":93.944,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":86.271,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€120.47Average Price Target€108.82Lowest Price Target€102.63
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bank of America Securities Analyst forecast on DE:ABL
Travis Steed
Bank of America Securities
Bank of America Securities
€102.63
Buy
12.68%
Upside
Reiterated
10/30/26
Analysts' Top Healthcare Picks: Veeva Systems (VEEV), Abbott Laboratories (ABT)
Argus Research Analyst forecast on DE:ABL
David Toung
Argus Research
Argus Research
―
Hold
―
Downgraded
10/26/26
Abbott downgraded to Hold from Buy at ArgusAbbott downgraded to Hold from Buy at Argus
Evercore ISI Analyst forecast on DE:ABL
Vijay Kumar
Evercore ISI
Evercore ISI
€110.66→€107.09
Buy
17.58%
Upside
Reiterated
10/23/26
Abbott price target lowered to $120 from $124 at Evercore ISIAbbott price target lowered to $120 from $124 at Evercore ISI
Wells Fargo Analyst forecast on DE:ABL
Larry Biegelsen
Wells Fargo
Wells Fargo
€106.2→€107.09
Buy
17.58%
Upside
Reiterated
10/23/26
Wells Fargo Issues a Buy Rating on Abbott Laboratories (ABT)
Oppenheimer Analyst forecast on DE:ABL
Unknown Analyst
Oppenheimer
Not Ranked
Oppenheimer
€102.63
Buy
12.68%
Upside
Reiterated
10/22/26
Oppenheimer Sticks to Their Buy Rating for Abbott Laboratories (ABT)
Piper Sandler Analyst forecast on DE:ABL
Adam Maeder
Piper Sandler
Piper Sandler
€105.3
Buy
15.62%
Upside
Reiterated
10/22/26
Piper Sandler Keeps Their Buy Rating on Abbott Laboratories (ABT)
J.P. Morgan Analyst forecast on DE:ABL
Robbie Marcus
J.P. Morgan
J.P. Morgan
€107.09→€105.3
Buy
15.62%
Upside
Reiterated
10/22/26
Abbott price target lowered to $118 from $120 at JPMorganAbbott price target lowered to $118 from $120 at JPMorgan
Barclays Analyst forecast on DE:ABL
Christopher Pasquale
Barclays
Barclays
€107.09
Buy
17.58%
Upside
Reiterated
10/22/26
Analysts Conflicted on These Healthcare Names: Elevance Health (NYSE: ELV), Moderna (NASDAQ: MRNA) and Abbott Laboratories (NYSE: ABT)
Robert W. Baird Analyst forecast on DE:ABL
David Rescott
Robert W. Baird
Robert W. Baird
€107.98→€109.77
Buy
20.52%
Upside
Reiterated
10/22/26
Abbott price target raised to $123 from $121 at BairdAbbott price target raised to $123 from $121 at Baird
TD Cowen Analyst forecast on DE:ABL
Josh Jennings
TD Cowen
TD Cowen
€120.47→€105.3
Buy
15.62%
Upside
Assigned
10/22/26
Abbott price target lowered to $118 from $135 at TD CowenAbbott price target lowered to $118 from $135 at TD Cowen
Citi Analyst forecast on DE:ABL
Joanne Wuensch
Citi
Citi
€111.55→€108.87
Buy
19.54%
Upside
Assigned
10/22/26
Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (NASDAQ: IONS), Maze Therapeutics, Inc. (NASDAQ: MAZE) and Abbott Laboratories (NYSE: ABT)
Stifel Nicolaus Analyst forecast on DE:ABL
Rick Wise
Stifel Nicolaus
Stifel Nicolaus
€107.09
Buy
17.58%
Upside
Reiterated
10/22/26
Stifel Nicolaus Sticks to Their Buy Rating for Abbott Laboratories (ABT)
RBC Capital Analyst forecast on DE:ABL
Kendall Au
RBC Capital
RBC Capital
€116.01→€111.55
Buy
22.48%
Upside
Assigned
10/21/26
Analysts Conflicted on These Healthcare Names: United Therapeutics (NASDAQ: UTHR), Elevance Health (NYSE: ELV) and Abbott Laboratories (NYSE: ABT)
BTIG Analyst forecast on DE:ABL
Marie Thibault
BTIG
BTIG
€119.58→€111.55
Buy
22.48%
Upside
Reiterated
10/21/26
Analysts Are Bullish on These Healthcare Stocks: Abbott Laboratories (ABT), Kazia Therapeutics (KZIA)
Leerink Partners Analyst forecast on DE:ABL
Unknown Analyst
Leerink Partners
Not Ranked
Leerink Partners
―
Hold
―
Reiterated
10/12/26
Abbott Laboratories (ABT) Gets a Hold from Leerink Partners
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bank of America Securities Analyst forecast on DE:ABL
Travis Steed
Bank of America Securities
Bank of America Securities
€102.63
Buy
12.68%
Upside
Reiterated
10/30/26
Analysts' Top Healthcare Picks: Veeva Systems (VEEV), Abbott Laboratories (ABT)
Argus Research Analyst forecast on DE:ABL
David Toung
Argus Research
Argus Research
―
Hold
―
Downgraded
10/26/26
Abbott downgraded to Hold from Buy at ArgusAbbott downgraded to Hold from Buy at Argus
Evercore ISI Analyst forecast on DE:ABL
Vijay Kumar
Evercore ISI
Evercore ISI
€110.66→€107.09
Buy
17.58%
Upside
Reiterated
10/23/26
Abbott price target lowered to $120 from $124 at Evercore ISIAbbott price target lowered to $120 from $124 at Evercore ISI
Wells Fargo Analyst forecast on DE:ABL
Larry Biegelsen
Wells Fargo
Wells Fargo
€106.2→€107.09
Buy
17.58%
Upside
Reiterated
10/23/26
Wells Fargo Issues a Buy Rating on Abbott Laboratories (ABT)
Oppenheimer Analyst forecast on DE:ABL
Unknown Analyst
Oppenheimer
Not Ranked
Oppenheimer
€102.63
Buy
12.68%
Upside
Reiterated
10/22/26
Oppenheimer Sticks to Their Buy Rating for Abbott Laboratories (ABT)
Piper Sandler Analyst forecast on DE:ABL
Adam Maeder
Piper Sandler
Piper Sandler
€105.3
Buy
15.62%
Upside
Reiterated
10/22/26
Piper Sandler Keeps Their Buy Rating on Abbott Laboratories (ABT)
J.P. Morgan Analyst forecast on DE:ABL
Robbie Marcus
J.P. Morgan
J.P. Morgan
€107.09→€105.3
Buy
15.62%
Upside
Reiterated
10/22/26
Abbott price target lowered to $118 from $120 at JPMorganAbbott price target lowered to $118 from $120 at JPMorgan
Barclays Analyst forecast on DE:ABL
Christopher Pasquale
Barclays
Barclays
€107.09
Buy
17.58%
Upside
Reiterated
10/22/26
Analysts Conflicted on These Healthcare Names: Elevance Health (NYSE: ELV), Moderna (NASDAQ: MRNA) and Abbott Laboratories (NYSE: ABT)
Robert W. Baird Analyst forecast on DE:ABL
David Rescott
Robert W. Baird
Robert W. Baird
€107.98→€109.77
Buy
20.52%
Upside
Reiterated
10/22/26
Abbott price target raised to $123 from $121 at BairdAbbott price target raised to $123 from $121 at Baird
TD Cowen Analyst forecast on DE:ABL
Josh Jennings
TD Cowen
TD Cowen
€120.47→€105.3
Buy
15.62%
Upside
Assigned
10/22/26
Abbott price target lowered to $118 from $135 at TD CowenAbbott price target lowered to $118 from $135 at TD Cowen
Citi Analyst forecast on DE:ABL
Joanne Wuensch
Citi
Citi
€111.55→€108.87
Buy
19.54%
Upside
Assigned
10/22/26
Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (NASDAQ: IONS), Maze Therapeutics, Inc. (NASDAQ: MAZE) and Abbott Laboratories (NYSE: ABT)
Stifel Nicolaus Analyst forecast on DE:ABL
Rick Wise
Stifel Nicolaus
Stifel Nicolaus
€107.09
Buy
17.58%
Upside
Reiterated
10/22/26
Stifel Nicolaus Sticks to Their Buy Rating for Abbott Laboratories (ABT)
RBC Capital Analyst forecast on DE:ABL
Kendall Au
RBC Capital
RBC Capital
€116.01→€111.55
Buy
22.48%
Upside
Assigned
10/21/26
Analysts Conflicted on These Healthcare Names: United Therapeutics (NASDAQ: UTHR), Elevance Health (NYSE: ELV) and Abbott Laboratories (NYSE: ABT)
BTIG Analyst forecast on DE:ABL
Marie Thibault
BTIG
BTIG
€119.58→€111.55
Buy
22.48%
Upside
Reiterated
10/21/26
Analysts Are Bullish on These Healthcare Stocks: Abbott Laboratories (ABT), Kazia Therapeutics (KZIA)
Leerink Partners Analyst forecast on DE:ABL
Unknown Analyst
Leerink Partners
Not Ranked
Leerink Partners
―
Hold
―
Reiterated
10/12/26
Abbott Laboratories (ABT) Gets a Hold from Leerink Partners
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AORTArtivion
MDWDMediwound
IMUXImmunic
RZLTRezolute
DFTXDefinium Therapeutics
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Abbott Laboratories

3 Months
Matthew TaylorJefferies
Success Rate
17/23 ratings generated profit
74%
Average Return
+2.97%
Copying Matthew Taylor's trades and holding each position for 3 Months would result in 73.91% of your transactions generating a profit, with an average return of +2.97% per trade.
1 Year
Jayson BedfordRaymond James
Success Rate
34/43 ratings generated profit
79%
Average Return
+14.84%
Copying Jayson Bedford's trades and holding each position for 1 Year would result in 79.07% of your transactions generating a profit, with an average return of +14.84% per trade.
2 Years
Matthew TaylorJefferies
Success Rate
17/23 ratings generated profit
74%
Average Return
+27.59%
Copying Matthew Taylor's trades and holding each position for 2 Years would result in 73.91% of your transactions generating a profit, with an average return of +27.59% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ABL Analyst Recommendation Trends

Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
0
0
0
0
0
Buy
38
33
42
36
39
Hold
5
0
0
0
2
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
43
33
42
36
41
In the current month, ABL has received 39 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. ABL average Analyst price target in the past 3 months is 108.82.
Each month's total comprises the sum of three months' worth of ratings.

ABL Financial Forecast

ABL Earnings Forecast

Next quarter’s earnings estimate for ABL is €1.46 with a range of €1.45 to €1.46. The previous quarter’s EPS was €1.27. ABL beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year ABL has Performed in-line its overall industry.
Next quarter’s earnings estimate for ABL is €1.46 with a range of €1.45 to €1.46. The previous quarter’s EPS was €1.27. ABL beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year ABL has Performed in-line its overall industry.

ABL Sales Forecast

Next quarter’s sales forecast for ABL is €11.78B with a range of €11.71B to €11.97B. The previous quarter’s sales results were €11.60B. ABL beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year ABL has Performed in-line its overall industry.
Next quarter’s sales forecast for ABL is €11.78B with a range of €11.71B to €11.97B. The previous quarter’s sales results were €11.60B. ABL beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year ABL has Performed in-line its overall industry.

ABL Stock Forecast FAQ

What is DE:ABL’s average 12-month price target, according to analysts?
Based on analyst ratings, Abbott Laboratories’s 12-month average price target is 108.82.
    What is DE:ABL’s upside potential, based on the analysts’ average price target?
    Abbott Laboratories has 19.47% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Abbott Laboratories a Buy, Sell or Hold?
          Abbott Laboratories has a consensus rating of Strong Buy, which is based on 17 buy ratings, 2 hold ratings and 0 sell ratings.
            What is Abbott Laboratories’s share price target?
            The average share price target for Abbott Laboratories is 108.82. This is based on 19 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €120.47 ,and the lowest forecast is €102.63. The average share price target represents 19.47% Increase from the current price of €91.08.
              What do analysts say about Abbott Laboratories?
              Abbott Laboratories’s analyst rating consensus is a Strong Buy. This is based on the ratings of 19 Wall Streets Analysts.
                How can I buy shares of Abbott Laboratories?
                To buy shares of DE:ABL, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.